ADBE vs MRK: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
Adobe Inc. · Technology
$219.72
+45.0% upside to fair value
Grade B
High Quality
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
ADBE has more upside to fair value
(+45.0%).
ADBE trades at a lower forward P/E
(12.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
MRK |
| Current Price |
$219.72 |
$113.87 |
| Fair Value Estimate |
$318.59 |
$100.14 |
| Upside to Fair Value |
+45.0%
|
-12.1%
|
| Market Cap |
$87.3B |
$281.2B |
| Forward P/E |
12.6x
|
32.0x
|
| EV / EBITDA |
9.0x
|
17.3x
|
| Price / Sales |
3.5x
|
4.3x
|
| Price / FCF |
8.2x
|
19.9x
|
| Revenue Growth YoY |
+12.7%
|
+4.3%
|
| Gross Margin |
89.1%
|
75.9%
|
| Operating Margin |
36.1%
|
27.6%
|
| Return on Equity |
62.4%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
12.17%
|
5.02%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Adobe Inc. is a leading software company specializing in digital media and digital experience solutions, driven primarily by subscription-based revenue models. The company benefits from a high-quality business model characterized by a durable competitive moat, strong margins with a gross margin of 89.1% and operating margin of 36.1%, and robust return on equity at 62.4%. Despite solid revenue gro…
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
ADBE |
MRK |
| Zone Low |
$238.94 |
$75.11 |
| Zone High |
$270.80 |
$85.12 |
| In Buy Zone? |
Yes
|
No
|